Background
==========

Type 1 diabetes mellitus (T1DM) is a multifactorial disease with a strong genetic component \[[@B1]\]. The main genetic contribution to T1DM susceptibility lies in the major histocompatibility complex (MHC) on the short arm of chromosome 6; several non-MHC chromosomal regions are also involved \[[@B2]\]. Several approaches have been used to identify T1DM susceptibility regions, including case-control studies of candidate genes \[human leukocyte antigen (HLA), insulin gene regulatory region, interleukin-1 receptor type 1 (ILIR1)\] \[[@B3],[@B4],[@B5],[@B6]\], combined linkage and association-based studies of candidate genes \[cytotoxic T lymphocyte associated-4 (CTLA-4)\] \[[@B7]\], and systematic total genome searches in addition to analyses of individual chromosomal regions \[[@B8],[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16]\].

There are clear differences in immunogenetic predisposition to T1DM between countries, and disease incidence seems to vary along with these differences in predisposition \[[@B1]\]. The incidence of T1DM in Southern India (10.4/100000 cases per year) is similar to that in Asian children in the UK and Caucasian children of European extraction \[[@B17],[@B18]\]. While an MHC component is apparent \[[@B19],[@B20]\] in T1DM susceptibility in Southern India, no association with either the insulin gene \[[@B20]\] or ILIR1 \[[@B6]\] has been found there in case-control studies. This suggests possible differences in the non-MHC T1DM component between Southern Indians and Caucasians of European extraction. In the latter population, an association with the insulin gene has been universally reported \[[@B4],[@B5],[@B21]\], and an IL1R1 association with T1DM has been reported in some Northern Europeans \[[@B6],[@B22]\].

VDR gene polymorphisms influence susceptibility to osteoporosis \[[@B23],[@B24],[@B25]\], primary hyperparathyroidism \[[@B26],[@B27]\], and autoimmune diseases such as Graves\' disease \[[@B28],[@B29]\], Hashimoto\'s thyroiditis \[[@B30]\], and multiple sclerosis \[[@B31]\]. Allelic variation in VDR also influences susceptibility to T1DM in Indian Asians \[[@B17]\], Germans \[[@B32]\], and Taiwanese \[[@B33]\]. There are six known polymorphisms in the VDR locus: an exon 2 initiation codon polymorphism, which is detected with *Fok*I restriction enzyme \[[@B34],[@B35],[@B36],[@B37]\], the *Bsm*I, *Tru9*I, and *Apa*I restriction fragment length polymorphisms (RFLPs) located between exons 8 and 9 \[[@B23],[@B38]\], the *Taq*I RFLP located in exon 9 \[[@B23]\], and a poly A polymorphism downstream of the 3\' untranslated region \[[@B39],[@B40]\]. There is apparently no significant linkage disequilibrium between the *Fok*I polymorphism and the *Bsm*I, *Apa*I, and *Taq*I polymorphisms \[[@B34],[@B35],[@B36],[@B37]\]. In this study, we analyzed the exon 2 initiation codon (VDR-*Fok*I) gene polymorphism in Japanese patients with T1DM. We also investigated associations between this VDR polymorphism and GAD65 antibody (Ab) status, an immune marker.

Subjects and Methods
====================

Subjects
--------

The study population comprised 110 unrelated Japanese T1DM patients (50 men and 60 women) from the Tokyo metropolitan area. T1DM was diagnosed on the basis of sudden-onset of severe symptoms or rapid progress to overt diabetes and dependence on exogenous insulin due to absolute insulin deficiency, according to the 1997 Committee of the American Diabetes Association (Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997) criteria. All subjects were insulin-dependent at the time of the study, although their β-cell reserve, estimated by measurement of fasting serum C-peptide, was variable. Slowly progressive T1DM was not included in this study. Mean age at onset of T1DM was 26.0 ± 3.7 years (mean ± SEM). GAD65 antibodies were assessed in 78 patients. Two hundred and fifty unrelated Japanese subjects (100 men and 150 women) without clinical evidence or family history of diabetes mellitus or autoimmune disease were selected as controls. The controls used in the present study are identical with the previously published controls \[[@B28],[@B29],[@B30]\]. This study was carried out in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from patients and controls.

Genotype analysis
-----------------

Genomic DNA was isolated from whole blood with the Genomix kit (Talent, Trieste, Italy). Primers VDR2a (5\'-AGCTGGCCCTGGCACTGACTCTTGCTCT-3\') and VDR2b (5\'-ATGGAAACACCTTGCTTCTTCTCCCTC-3\') and 100 ng of genomic DNA were combined in a polymerase chain reaction (PCR) mixture to amplify a 265-bp fragment containing the polymorphism in the initiation codon of VDR \[[@B34]\]. PCR products were digested with *Fok*I at 37°C for 3 h and then subjected to electrophoresis in 2% agarose gel containing ethidium bromide. Cleavage of homozygous DNA carrying the *Fok*I polymorphism (FF) generates 69-bp and 196-bp fragments. Restriction endonuclease cleavage analysis of DNA heterozygous for the *Fok*I polymorphism (Ff) results in uncleaved (265-bp) DNA as well as the 69-bp and 196-bp products. Homozygous DNA that does not carry the *Fok*I polymorphism (ff) is not cleaved by *Fok*I and appears as a single 265-bp fragment on agarose gels.

Measurement of GAD65 antibody
-----------------------------

GAD65 Ab was detected with a radioligand binding assay described previously \[[@B41]\]. Intra- and inter-assay coefficients of variation were less than 5%. At the First International GAD Autoantibody Workshop, our GAD65 Ab assay yielded 100% sensitivity (% positive samples confirmed to be positive) and 100% specificity (% known negative samples confirmed to be negative).

Statistical analysis
--------------------

Genotypes and alleles in patients and controls were compared with the Χ^2^-tests for 2 × 2 and 2 × 3 tables and by Fisher\'s exact test. Relative risk was calculated by Woolf\'s method \[[@B42]\]. *P* \< 0.05 was considered significant. We corrrected for multiple testing using the Bonferoni correction.

Results
=======

Genotype and allele frequencies of the VDR-FokI gene polymorphism in patients and controls
------------------------------------------------------------------------------------------

PCR-RFLP was used to examine VDR-*Fok*I genotype distributions in T1DM patients and controls (Table [1](#T1){ref-type="table"}). The distribution of VDR genotypes was similar between the male and female control subjects (data not shown). The genotype distribution in our control subjects was similar to that in a previously reported group of Japanese women who resided in Kagawa prefecture \[[@B25]\].

###### 

VDR-*Fok*I polymorphism in study subjects

                             T1DM patients   Controls
  -------------------------- --------------- ----------
  Genotype frequencies^a^                    
   FF                        52(47%)         82 (33%)
   Ff                        52(47%)         138(55%)
   ff                        6 (6%)          30 (12%)
  Allele frequencies^b^                      
   F                         156 (71%)       302(60%)
   f                         64 (29%)        198(40%)
  Phenotype frequencies^c^                   
   F positive                104 (95%)       220(88%)
   f positive                58 (53%)        168(67%)

Values shown are the number of subjects (percentage in parentheses). ^a^Χ^2^ test of heterogeneity between T1DM patients and control subjects. Χ^2^ = 8.48, 2 degrees of freedom; *P* = 0.014. ^b^Χ^2^ test of heterogeneity between T1DM patients and control subjects. Χ^2^ = 7.29, 1 degree of freedom; *P* = 0.0069. ^c^Relative risk ratio for F phenotype = 2.4.

The distribution of genotype frequencies differed significantly between T1DM patients and controls (Χ^2^ = 8.48, 2 degrees of freedom, *P* = 0.014), with the VDR FF genotype occurring more frequently in the T1DM patients. The distribution of allele frequencies differed significantly between T1DM patients and controls (Χ^2^ = 7.29, 1 degree of freedom, *P* = 0.0069). The relative risk conferred by at least one F allele (FF or Ff) was 2.4.

Genotype distributions among patients and controls did not differ according to age, height, or weight (data not shown). No significant linkage disequilibrium was detected between this polymorphism and the *Bsm*I polymorphism in intron 8 and exon 9 in the T1DM patients (data not shown).

VDR-FokI gene polymorphism in GAD65-antibody-positive and -negative subjects
----------------------------------------------------------------------------

We investigated association between VDR-*Fok*I gene polymorphism and GAD65-Ab positivity in 78 patients (Table [2](#T2){ref-type="table"}). The distribution of genotype frequencies differed significantly between GAD65-Ab-positive patients and controls (Χ^2^ = 8.14, 2 degrees of freedom, *P* = 0.017). The distribution of allele frequencies also differed significantly between GAD65-Ab-positive T1DM patients and controls (Χ^2^ = 6.32, 1 degree of freedom, *P* = 0.012). The relative risk conferred by at least one F allele (FF or Ff) was 2.0. The distribution of genotype and allele frequencies did not differ significantly between GAD65-Ab-negative T1DM patients and controls (Χ^2^ = 0.78, 2 degrees of freedom, *P* = 0.68 and Χ^2^ = 0.19, 1 degree of freedom, *P* = 0.66). The genotype and allele distributions in the GAD65-Ab-positive and -negative patients did not differ significantly (Χ^2^ = 3.36, 2 degrees of freedom, *P* = 0.19 and Χ^2^ = 1.98, 1 degree of freedom, *P* = 0.16, respectively).

###### 

VDR-*Fok*I polymorphism in study subjects analyzed with respect to GAD65 antibody status

                             GAD65-positive   GAD65-negative   Controls
  -------------------------- ---------------- ---------------- -----------
  Genotype frequencies^a^                                      
   FF                        26 (54%)         10(33%)          82 (33%)
   Ff                        19 (40%)         18(60%)          138 (55%)
   ff                        3(6%)            2(7%)            30 (12%)
  Allele frequencies^b^                                        
   F                         71 (74%)         38(63%)          302(60%)
   f                         25 (26%)         22(37%)          198(40%)
  Phenotype frequencies^c^                                     
   F positive                45 (94%)         28 (94%)         220(88%)
   f positive                22 (46%)         20 (67%)         168(67%)

Values shown are the number of subjects with the percentage in parentheses. ^a^Χ^2^ test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ^2^ = 8.14, 2 degrees of freedom; *P* = 0.017. ^b^Χ^2^ test of heterogeneity between GAD65-positive T1DM patients and control subjects. Χ^2^ = 6.32, 1 degree of freedom; *P* = 0.012. ^c^Relative risk ratio for F phenotype (GAD65-positive T1DM) = 2.0.

Discussion
==========

We found an association between the VDR-*Fok*I polymorphism and T1DM in our study population. Selective β-cell destruction, which is observed in T1DM, is thought to be caused by a T-cell-mediated autoimmune process \[[@B43]\]. Genetic susceptibility to T1DM is well established, and certain HLA pheno- and genotypes are associated with T1DM; for example, HLA-DR 3 and -DR 4 in Caucasian populations \[[@B43]\], and HLA-DR 4 and -DR 9 in Japanese populations \[[@B44]\]. Recent genome-wide searches and several candidate gene studies have revealed new regions possibly associated with T1DM \[[@B8],[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B45],[@B46]\].

Vitamin D hormone has important immunomodulatory properties and influences insulin secretion \[[@B47]\]. This hormone inhibits T-cell activation both *in vitro* and *in vivo* and the secretion of IL-1, IL-2, IL-6, IL-12, TNF, and interferon (IFN)-γ \[[@B48],[@B49],[@B50],[@B51]\]. These cytokines play important roles in the development of T cells, which are believed to be involved in the pathogenesis of several chronic inflammatory autoimmune diseases \[[@B52]\]. In recent studies, 1,25-dihydroxyvitamin D3 was shown to inhibit IL-12 production by macrophages and dendritic cells by suppressing transcriptional activation of the p35 and p45 genes, which code for subunits of IL-12. Transcriptional repression of the p40 gene is dependent on expression of VDR \[[@B53]\]. In murine models, vitamin D administration prevents development of T1DM as well as the associated autoimmune insulitis \[[@B54]\]. In Bangladeshi subjects, vitamin D levels were found to be reduced in those subjects most at risk for type 2 diabetes \[[@B55]\].

The VDR locus has been studied extensively for association with susceptibility to osteoporosis \[[@B23],[@B24],[@B25]\], primary hyperparathyroidism \[[@B26],[@B27]\], and autoimmune diseases such as Graves\' disease \[[@B28],[@B29]\], Hashimoto\'s thyroiditis \[[@B30]\], and multiple sclerosis \[[@B31]\]. The *Bsm*I B allele of VDR has been associated with reduced bone mineral density in some studies \[[@B23],[@B56]\], but not in others \[[@B57],[@B58]\], and at least one study showed the b allele of VDR to be associated with particular subtypes of osteoporosis \[[@B59]\]. The bb genotype has been associated with primary hyperparathyroidism in Swedish patients \[[@B26],[@B27]\] and multiple sclerosis in Japanese patients \[[@B31]\]. The *Fok*I FF genotype for VDR has been associated with both Graves\' disease \[[@B28]\] and Hashimoto\'s thyroiditis \[[@B30]\] in Japanese patients.

The role of the VDR gene in T1DM has also been examined \[[@B17],[@B32]\]. Evidence for preferential transmission of the VDR b allele to affected offspring has been found in Indian Asians \[[@B17]\]. Pani et al. \[[@B32]\] detected significant haplotype-wise extended transmission disequilibrium for the *Bsm*I/*Apa*I/*Taq*I, *Bsm*I/*Taq*I, and *Apa*I/*Taq*I haplotypes in Germans; analysis of the *Fok*I site did not provide additional information on susceptibility. Recently, Chang et al. confirmed the association of these markers with T1DM in the Taiwanese population \[[@B33]\]. Allelic frequencies for this and other VDR RFLPs (*Apa*I, *Taq*I) differ between Caucasian and Japanese subjects \[[@B24],[@B60]\]. RFLP analysis of VDR revealed that the BBAAtt genotype is relatively common (16.7%) in Caucasian populations and rare in Japanese populations (1.4%) \[[@B24]\]. Therefore, we investigated VDR-*Fok*I polymorphism in this study. Our investigation of VDR-*Fok*I genotype frequencies in Japanese subjects revealed that the FF genotype is significantly more common in T1DM patients (47%) than in control subjects (33%), suggesting that patients with this genotype may be predisposed to T1DM \[[@B28]\].

In contrast to our findings for T1DM, an increased frequency of the F allele, because it encodes a VDR isoform with higher transcriptional activity, has a beneficial effects in the prevention of osteoporosis, and should lead to higher immunomodulatory activity of the vitamin D hormone \[[@B61]\]. Recently, Colin et al. \[[@B62]\] demonstrated in peripheral blood mononuclear cells with a natural VDR genotype a direct functional consequence of the VDR-*Fok*I polymorphism for the action of 1,25-dihydroxyvitamin D3. They found that the FF genotype had a significant lower ED~50~ than the Ff genotype corresponding to an allele dose effect of 0.32 nM per f allele copy (*P* = 0.0036), while for *Bsm*I genotypes no differences in ED~50~ were observed \[[@B62]\]. The apparent discrepancy could be due to the effect of the genetic susceptibility to T1DM and ethnic differences related to VDR-*Fok*I allelic prevalences as well as to environmental and geographic variations in calcium intake, exposure to sunshine, or other factors.

In the present study, the FF genotype (or presence of the F allele) of the VDR-*Fok*I polymorphism was also associated with GAD65-Ab-positive T1DM in the Japanese population, although the absence of a significant difference between GAD65-Ab-negative patients and controls might be simply due to the small sample size of patients tested for GAD65 antibodies. McDermott et al. \[[@B17]\] found no relation between the VDR-*Bsm*I, -*Taq*I, or -*Apa*I polymorphism and GAD65 Ab status in Indian Asians. Thus, since there is apparently no linkage disequilibrium between *Fok*I polymorphism and *Bsm*I, *Apa*I, and *Taq*I polymorphisms \[[@B34],[@B35],[@B36],[@B37]\], the VDR-*Fok*I polymorphism seems to contribute to immunological heterogeneity of T1DM, although the mechanism remains unclear. Although no *in vitro* or animal studies have shown that VDR function is directly associated with antibody production in autoimmune disease or that this polymorphism might alter immune function, GAD65-Ab-negative diabetes patients could be subject to a different disease process or a different path of clinical development with regards to a possible VDR contribution. Both possibilities warrant further study.

Conclusions
===========

In conclusion, our data indicates an association between the VDR gene and T1DM among the Japanese. We suggest that the FF genotype may predispose Japanese individuals to T1DM and that this genotype appears to be a marker for T1DM. The role of the VDR gene polymorphism should be studied further in other populations, and other polymorphisms, such as the *Bsm*I, *Apa*I, *Tru9*I and *Taq*I polymorphisms, should be analyzed for association with T1DM susceptibility. In addition, the VDR-*Fok*I polymorphism showed a possible association with GAD65-Ab-positive T1DM. The VDR plays a role in lymphocyte response to microorganisms (tuberculin reactive status in pulmonary tuberculosis, leprosy etc.). Thus, it is conceivable that it may also be involved in immune response to self antigens e.g. GAD65 antibodies.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/content/backmatter/1471-2350-2-7-b1.pdf>

Acknowledgments
===============

This work was supported, in part, by the High-Technology Research Center Project from the Ministry of Education, Science, Sports and Culture of Japan.

Competing interests

Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this paper? No.

Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper? No.

Do you have any other financial competing interests? No.

Are there any non-financial competing interests you would like to declare in relation to this paper? No.
